SecBot SecBot
6-K ·Filed Mar 26, 2026

VALN

Valneva SE
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001628280-26-021321
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for any data readouts or partnership announcements from Valneva's presentations at the World Vaccine Congress, which could provide early signals of commercial traction or regulatory progress for IXCHIQ.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.32
T+0 close · Mar 26, 2026 · via day close
Latest settled
−15.35%
T+60 · $5.35
Vs SPY
−29.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $6.32entry
  2. T+1 · 8mo ago −2.37%α −0.69% · $6.17
  3. T+5 · 8mo ago −3.48%α −5.11% · $6.10
  4. T+20 · 7mo ago −12.97%α −23.64% · $5.50
  5. T+60 · 5mo ago −15.35%α −29.30% · $5.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Valneva announced its participation in the 26th World Vaccine Congress in Washington, DC, where it will present updates on its chikungunya vaccine IXCHIQ, including real-world evidence from a pilot vaccination campaign in Brazil involving over 12,000 individuals. The company will also engage in discussions on mosquito-borne diseases and meet with current and potential partners.

Key Facts

  • Valneva will present chikungunya vaccine IXCHIQ Phase IV and real-world evidence data at the World Vaccine Congress on April 1, 2026.
  • Over 12,000 people have been vaccinated in a pilot campaign in Brazil with IXCHIQ, conducted in partnership with Instituto Butantan.
  • The data presented will support post-marketing commitments and evaluate the real-world effectiveness and safety of IXCHIQ.
  • Valneva executives will participate in a panel discussion on mosquito-borne vaccines and outbreak response.
  • The company will maintain a presence at booth #538 to meet with partners.

Financial Impact

Not specified

Risk Factors

  • The filing contains forward-looking statements subject to risks including regulatory delays, manufacturing challenges, and uncertain clinical outcomes.
  • Real-world data may reveal safety or efficacy concerns not seen in clinical trials, potentially impacting commercial adoption.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-021321
Document: a6-kcoverpagetemplate.htm0001628280-26-021321
Document: 0001628280-26-021321-index-headers.html0001628280-26-021321
Document: 0001628280-26-021321-index.html0001628280-26-021321
Document: 0001628280-26-021321.txt0001628280-26-021321

US Market Status

Market Closed · Opens Wed (10h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026